Skip to main content

Table 1 Summary of PIDD Categories

From: A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases

Major category

Subcategory

1. Immunodeficiencies affecting cellular and humoral immunity

• Severe combined immunodeficiencies, defined by CD3 T cell lymphopenia

• Combined immunodeficiencies generally less profound than severe combined immunodeficiency

2. Combined immunodeficiencies with associated or syndromic features

• Immunodeficiency with congenital thrombocytopenia

• DNA repair defects other than those listed in major category 1

• Thymic defects with additional congenital anomalies

• Immuno-osseous dysplasias

• Hyper IgE syndromes

• Dyskeratosis congenita, myelodysplasia, short telomeres

• Defects of vitamin B12 and folate metabolism

• Anhidrotic ectodermal dysplasia with immunodeficiency

• Calcium channel defects

• Others

3. Predominantly antibody deficiencies

• Hypogammaglobulinemia

• X-linked (Bruton’s) agammaglobulinemia (severe reduction in all serum immunoglobulin isotypes with profoundly decreased or absent B cells)

• Other antibody deficiencies

  • Severe reduction in at least 2 serum immunoglobulin isotypes with normal or low number of B cells, CVID phenotype

  • Severe reduction in serum IgG and IgA with normal/elevated IgM and normal numbers of B cells, hyper IgM

  • Isotype, light chain, or functional deficiencies with generally normal numbers of B cells

4. Diseases of immune dysregulation

• HLH and EBV susceptibility

• Syndromes with autoimmunity and others

5. Congenital defects of phagocyte number or function or both

• Congenital neutropenias

• Functional defects

  • Defects of respiratory burst (chronic granulomatous disease)

  • Other non-lymphoid defects

6. Defects in intrinsic and innate immunity

• Bacterial and parasitic infections

• Mendelian susceptibility to mycobacterial disease and viral infection

7. Autoinflammatory disorders

• Recurrent inflammation

• Systemic inflammation with urticarial rash

• Sterile inflammation (skin/bone/joints)

• Type 1 interferonopathies

• Others

8. Complement deficiencies

• Susceptibility to infection

  • Disseminated neisserial infections

  • Recurrent pyogenic infections

  • SLE-like syndrome

  • Atypical hemolytic uremic syndrome

  • Others

9. Bone marrow failure

• Fanconi anemia

• Dyskeratosis congenita, myelodysplasia, defective telomere maintenance

10. Phenocopies of PIDD

• Associated with somatic mutations

• Associated with autoantibodies

  1. Adapted from Picard C et al. [5], Bousfiha A et al. [6]
  2. All categories of PIDD are FDA-approved indications for intravenous or subcutaneous immunoglobulin replacement therapy.
  3. CVID common variable immunodeficiency, EBV Epstein-Barr virus, FDA Food and Drug Administration, HLH hemophagocytic lymphohistiocytosis, IgA immunoglobulin A, IgE immunoglobulin E, IgG immunoglobulin G, IgM immunoglobulin M, PIDD primary immunodeficiency diseases, SLE systemic lupus erythematosus